HIV Treatment Adherence Dose Determination Trial

Sponsor
University of Connecticut (Other)
Overall Status
Recruiting
CT.gov ID
NCT04577313
Collaborator
National Institute of Mental Health (NIMH) (NIH)
400
2
2
51
200
3.9

Study Details

Study Description

Brief Summary

The proposed research will conduct the first dose-determination trial to find the optimal number of behavioral counseling sessions (dose) needed to achieve and sustain optimal HIV treatment adherence. The results of this study will determine how much intervention is needed for whom and at what cost to guide health policy and implementation of behavioral interventions designed to improve durable viral suppression.

Condition or Disease Intervention/Treatment Phase
  • Behavioral: Behavioral Self-Regulation Adherence Counseling
N/A

Detailed Description

The proposed research will conduct the first ever dose-determination trial of a behavioral intervention to improve engagement in HIV care, antiretroviral therapy (ART) adherence and HIV viral suppression. The trial is designed to inform the implementation of behavioral interventions, including several in CDC's Compendium of Evidence-Based Interventions. Behavioral counseling has the flexibility and reach to overcome numerous challenges to HIV care, including social, emotional, and structural barriers. However, basic questions of how to best implement and scale-up interventions remain unanswered, such as "how much intervention is needed to achieve HIV suppression in subgroups of patients facing individual and social challenges?" There are currently no dose-determination trials in the HIV behavioral intervention literature to guide implementation decisions and health service policy. In the proposed research the investigators specifically aim to: (a) determine the minimum effective dose of an evidence-based HIV treatment engagement and adherence intervention, (b) identify subgroups of patients requiring greater and fewer intervention resources to achieve and sustain viral suppression, and (c) the costs associated with intervention dose-response. Participants who are receiving ART with empirically determined low-adherence will be randomized to either: (a) the dose determination condition of weekly evidence-based behavioral self-regulation counseling until achieving HIV suppression or (b) fixed dose 5-weekly sessions of evidence-based behavioral self-regulation counseling sessions. The dose determination condition adjusts to patient needs and determines the dose to achieve optimal adherence / HIV suppression, in contrast to the fixed dose condition that does not adjust to patient response. The trial is therefore designed to determine the number of behavioral counseling intervention sessions needed to achieve and sustain HIV suppression. Once meeting criteria for adherence / viral suppressed, counseling in the dose-determination condition is suspended. In contrast, the fixed-dose condition is delivered in five prescribed sessions as disseminated by the CDC. Follow-up assessments commence for 12-months from baseline with the primary endpoint of 12-month blood plasma HIV viral load and secondary outcome of ART adherence. Response to counseling is defined by achieving viral suppression and non-response is defined by not achieving optimal adherence / viral suppression. Participants in both the dose-determination and fixed-session conditions who initially respond and rebound to unsuppressed viral load will receive additional counseling with redose-response monitored and analyzed. Longitudinal analyses will examine intervention dose for key patient subgroups and dose-response cost-effectiveness analyses to guide resource allocation and implementation decisions. This research is aimed at informing health policy makers and programmatic decisions regarding intervention implementation to increase the likelihood of sustained HIV suppression.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
400 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
Single (Outcomes Assessor)
Primary Purpose:
Treatment
Official Title:
DOSE DETERMINATION TRIAL: The Start/Persist Studies
Actual Study Start Date :
Sep 1, 2020
Anticipated Primary Completion Date :
Nov 30, 2023
Anticipated Study Completion Date :
Nov 30, 2024

Arms and Interventions

Arm Intervention/Treatment
Active Comparator: Continuous Counseling

Receives up to 16 weekly behavioral counseling sessions over the phone to achieve optimal medication adherence. Counseling adjusts to patient needs and determines the dose to achieve optimal adherence / HIV suppression, in contrast to the fixed dose condition that does not adjust to patient response.

Behavioral: Behavioral Self-Regulation Adherence Counseling
Telephone-delivered counseling to focus on cognitive-behavioral skills to improve HIV treatment adherence.

Active Comparator: Fixed Counseling

Receives up to five weekly behavioral counseling sessions over the phone focused on improving HIV medication adherence / viral suppression.

Behavioral: Behavioral Self-Regulation Adherence Counseling
Telephone-delivered counseling to focus on cognitive-behavioral skills to improve HIV treatment adherence.

Outcome Measures

Primary Outcome Measures

  1. Change in Antiretroviral Therapy Adherence from Baseline to 12-Months [12-Month]

    Medication adherence defined by percentage of medication doses taken as prescribed

  2. Change in HIV Viral Load from Baseline to 12-months [12-months]

    Blood plasma HIV RNA

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Confirmed HIV positive

  • Confirmed prescribed antiretroviral therapy

  • Confirmed non-adherent to anti-retroviral therapy

Exclusion Criteria:
  • Does not have access to a phone

  • Does not have access to the internet

Contacts and Locations

Locations

Site City State Country Postal Code
1 University of Connecticut Storrs Connecticut United States 06269
2 University of Connecticut Field Site Atlanta Georgia United States 30308

Sponsors and Collaborators

  • University of Connecticut
  • National Institute of Mental Health (NIMH)

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

Responsible Party:
Seth Kalichman, Professor, University of Connecticut
ClinicalTrials.gov Identifier:
NCT04577313
Other Study ID Numbers:
  • H19-161
  • R01MH121129
First Posted:
Oct 6, 2020
Last Update Posted:
Oct 15, 2021
Last Verified:
Oct 1, 2021
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Additional relevant MeSH terms:

Study Results

No Results Posted as of Oct 15, 2021